In a report released today, Jason Bednar from Piper Sandler reiterated a Buy rating on Henry Schein (HSIC – Research Report), with a price target of $78.00. The company’s shares closed yesterday at $67.50.
According to TipRanks, Bednar is an analyst with an average return of -10.4% and a 33.66% success rate. Bednar covers the Healthcare sector, focusing on stocks such as Align Tech, Henry Schein, and Cooper Co.
In addition to Piper Sandler, Henry Schein also received a Buy from Stifel Nicolaus’s Jonathan Block in a report issued yesterday. However, today, Robert W. Baird maintained a Hold rating on Henry Schein (NASDAQ: HSIC).
See Insiders’ Hot Stocks on TipRanks >>
HSIC market cap is currently $8.37B and has a P/E ratio of 20.05.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Henry Schein (HSIC) Company Description:
Henry Schein, Inc. engages in the provision of health care products and services to medical, dental, and veterinary office-based practitioners. It operates through the Healthcare Distribution, and Technology and Value-Added Services segments. The Healthcare Distribution segment includes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins. The Technology & Value-Added Services segment offers financial services on a non-recourse basis, e-services practice, technology, network and hardware services. The company was founded by Henry Schein and Esther Schein in 1932 and is headquartered in Melville, NY.
Read More on HSIC:
